164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence